Red X iconGreen tick iconYellow tick icon
A postgraduate research opportunity at the University of Otago.

Details

Close date
Friday, 19 February 2021
Academic background
Sciences, Health Sciences
Host campus
Christchurch
Qualification
Honours
Department
Pathology and Biomedical Science (Christchurch)
Supervisors
Dr Vanessa Lattimore, Associate Professor Logan Walker

Overview

Prevention is the ideal strategy for reducing the impact of breast and ovarian cancer. Prophylactic surgery is an effective option for minimising risk in individuals who are genetically predisposed to these diseases, however, it has considerable impacts that reduce quality of life of the patient. Antisense oligonucleotide therapy has been successful in reversing the symptoms of degenerative disorders by altering gene splicing. This study investigates whether can eliminate the impact of high-risk genetic variants by modifying splicing using antisense oligonucleotides. This project will lay the foundation for the development of novel risk-reducing therapies to prevent cancer in genetically predisposed individuals. The research project involves several molecular techniques including RT-PCR, qPCR and cell culture.

Preferred student expertise

Science student with an interest in molecular biology and genetics and who has laboratory experience.

Further information

This is one of a number of projects on offer for the 2021 intake of BBiomedSc(Hons) at the University of Otago, Christchurch campus.

UOC BBiomedSc(Hons) website

Dr Vanessa Lattimore's profile

Associate Professor Logan Walker's profile

Mackenzie Cancer Research Group website

Department of Pathology and Biomedical Science website

Contact

Dr Vanessa Lattimore
Tel +64 3 364 0557
Emailvanessa.lattimore@otago.ac.nz

Useful information

Similar research opportunities

Back to top